About
CalciMedica, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapies for acute and chronic conditions related to calcium-dependent pathways, particularly with its lead candidate, CM4620, aimed at addressing severe muscle cramps in sickle cell disease. The company utilizes a proprietary technology platform to create innovative calcium modulators and has assembled a strong pipeline bolstered by a veteran management team and strategic collaborations to accelerate clinical development. With its dedication to addressing critical unmet medical needs and transforming treatment landscapes, CalciMedica represents a unique and promising investment opportunity within the biopharmaceutical sector.
Advanced charting, extended hours trading, and free stock for new accounts.
Price data sourced from Polygon.io (previous trading day close). Fundamentals from Alpha Vantage. Insider trades from SEC EDGAR. Cached via Cloudflare KV.